SecBot SecBot
SECBOTREPLAY Home › Report › CRMD

CRMD · CorMedix reported strong Q4 and full-year 2025 results, driven by…

CorMedix, Inc. · PRESS-RELEASE filed Mar 5, 2026 at 07:30 ET

At the news

BULLISHIMPACT 8/10

PRESS-RELEASE filed Mar 5, 2026 at 07:30 ET

CorMedix reported strong Q4 and full-year 2025 results, driven by $128.6M in revenue (up 312% YoY) and $163.1M net income, a turnaround from a $17.9M loss in 2024. Growth was fueled by DefenCath sales and the full-quarter contribution from the Melinta acquisition. The company reiterated 2026 guidance and announced a $75M share repurchase program.

  • Q4 2025 net revenue was $128.6 million, up 312% from $31.2 million in Q4 2024
  • Full-year 2025 revenue was $311.7 million, with pro forma revenue of $401.3 million including Melinta
  • Q4 2025 net income was $14.0 million ($0.16 diluted EPS), compared to $13.5 million ($0.20 diluted EPS) in Q4 2024
  • Full-year 2025 net income was $163.1 million ($2.04 diluted EPS), versus a $17.9 million loss in 2024

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access